Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.

ABSTRACT:

Introduction/background

Traditional imaging assessment criteria might not correlate well with clinical benefit from vascular endothelial growth factor pathway-directed therapy in metastatic renal cancer. Preclinical data suggest tumor growth is preceded by a rise in K^trans level, a parameter derived from dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) that reflects vascular permeability. We thus hypothesized that K^trans might be a predictive biomarker for pazopanib.

Patients and methods

Patients with metastatic renal cancer were treated with pazopanib at 800 mg oral daily until disease progression. MRI of the abdomen and pelvis with a DCE-MRI sequence was obtained at baseline and every 8 weeks.

Results

Seventy-three DCE-MRI scans

SUBMITTER: Sweis RF 

PROVIDER: S-EPMC5315677 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature